SAN FRANCISCO – Dance Biopharm is working with Phillips-Medisize to develop a version of the Dance 501 “soft-mist” inhaled insulin device for diabetes that has data connectivity for better management of treatment. “We believe our inhaled insulin product is state of the art and well-differentiated from powder based, non-electronic technology,” said John Patton, chairman and CEO of Dance Biopharm, in a statement. “It provides a platform for applying advanced digital medicine for diabetes management.” The Dance 501 electronic inhaler utilizes a vibrating mesh technology, designed to produce consistently sized particles of liquid insulin in the form of a soft mist, allowing for efficient and consistent delivery of insulin into the lungs in a few breaths. “Dance’s breathable insulin technology will be a game changer for patients living with diabetes,” said Bill Welch, chief technology officer at Phillips-Medisize, in a statement. “Working closely with Dance to support a connected health strategy, product development and manufacturing can enable faster global access to Dance’s innovative insulin delivery solution.” Phillips-Medisize, a Molex company, is an outsource provider of design and manufacturing services to the drug delivery, consumable diagnostics, medical device and specialty commercial markets.
You are here: / / Dance Biopharm teams with Philips-Medisize for electronic soft mist insulin inhaler